+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

  • ID: 5116509
  • Report
  • March 2020
  • Region: China
  • 210 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 2Y-Chem
  • BioLingus
  • Dizal Pharmaceutical
  • Hetero
  • Novartis
  • Shanghai Hohance Chemical

Overview

Small molecule drugs represent nearly 90% of pharmaceutical products available in the market. In fact, in 2019, the FDA’s Center for Drug Evaluation and Research approved 48 drugs, of which, 67% were small molecules. However, drug development and manufacturing is a cost intensive process, and is, at times, characterized by the need for advanced capabilities and specialized facilities, which are not possible for all developer companies to build in-house. This has compelled many of the smaller companies to outsource a significant part of their manufacturing operations to contract service providers. Pharmaceutical contract manufacturing organizations (CMOs) offer a wide range of services, ranging from process R&D, and clinical / commercial scale manufacturing of APIs, intermediates and FDFs. Some of the benefits of engaging manufacturing service providers include access to larger production capacities, cost savings (for innovator companies) and reductions in time-to-market. In this context, the advantages of outsourcing to emerging global regions, especially in Asia, are well known. A number of western drug developers have already demonstrated the preference to outsource their manufacturing operations to CMOs or CDMOs in China.

Over the past few decades, the pharmaceutical market in China has evolved into the second largest in the world; as per certain industry experts, it is estimated to surpass USD 300 billion by the end of 2020. Similarly, the contract manufacturing market in the region has also grown into a prominent and promising segment of the pharmaceutical industry. The relatively lower manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, have led to the establishment of various pharmaceutical manufacturing facilities in China by both Chinese and non-China based service providers. The number of FDA approved API manufacturing facilities in the region has doubled during the period 2010-2019. In fact, as of October 2019, 13% of FDA approved pharmaceutical manufacturing facilities are situated in China. These service providers are focused on investing in the development of the necessary capabilities and capacity to stay ahead of the competition in this field. In light of the aforementioned facts, China has been one of the top preferences of pharmaceutical companies for API and FDF manufacturing projects, since the past few years.

We believe that, the changing supply chain scenario due to the recent COVID-19 outbreak is likely to have a prominent impact on the global contract manufacturing industry, including China, in the short term. Having said that, the steps being taken by the pharma players and contract manufacturers are likely to help stakeholders absorb this impact. As pharma companies resume full-scale operation after the coronavirus outbreak, the demand for large-scale contract manufacturing is expected to increase significantly.

Scope of the Report

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China. The study also features a detailed analysis, highlighting the capabilities of pharmaceutical CMOs in this region.

Amongst other elements, the report features:


  • A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of primary packaging and number of manufacturing facilities.
  • A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.  
  • A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
  • Brief profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile includes an overview of the company, information related to its pharmaceutical manufacturing service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.
  • A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] analysis by investments made, with detailed information on investments related to R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework, presenting a summary of all initiatives, and [C] a heat map representation highlighting the yearly distribution of the initiatives undertaken by each company.
  • A case study of the key recent developments (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs, during 2014-2020 (till February), based on several parameters, such as year of partnership, type of partnership and geography.
  • A detailed capacity analysis based on the individual reactor capacities of various industry stakeholders, taking into consideration parameters, such as company size (small-sized, mid-sized, large and very large), and location of the manufacturing facility (Eastern China, Southern China and Northern China).
  • A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as growth of the overall pharmaceutical drugs market in China, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] key geographical regions (Eastern China, Southern China, Northern China), [B] type of product (API and drug product), [C] type of drug product (solid, liquid / semi-solid, injectables, others), [D] scale of operation (clinical and commercial), [E] company size (small-sized, mid-sized, large / very large. To account for the uncertainties associated with the growth of the pharmaceutical drugs contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 2Y-Chem
  • BioLingus
  • Dizal Pharmaceutical
  • Hetero
  • Novartis
  • Shanghai Hohance Chemical

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of the Pharmaceutical Contract Manufacturing
3.3. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.3.1. Traditional CMOs
3.3.2. Modern CMOs
3.4 Need for Outsourcing in the Pharmaceutical Industry
3.5. Services Offered by CMOs
3.6. Pharmaceutical Contract Manufacturing Scenario in China
3.7. Advantages and Challenges associated with Outsourcing Pharmaceutical Manufacturing to China-based CMOs
4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Product (API and FDF)
5.2.4.1. Analysis by Type of Product and Location of Headquarters
5.2.5. Analysis by Highest Scale of Operation
5.2.6. Analysis by Type of FDF
5.2.6.1. Analysis by Type of Solid FDF
5.2.6.2. Analysis by Type of Liquid FDF
5.2.6.3. Analysis by Type of Powder FDF
5.2.6.4. Analysis by Type of Semi-Solid FDF
5.2.6.5. Analysis by Type of FDF and Region
5.2.7. Analysis by Type of Primary Packaging
5.3. Non-Chinese Pharmaceutical CMOs with Manufacturing Facilities in China: List of Companies
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Product (API and FDF)
5.3.4.1. Analysis by Type of Product and Region
5.3.5. Analysis by Highest Scale of Operation
5.3.6. Analysis by Type of FDF
5.3.6.1. Analysis by Type of Solid FDF
5.3.6.2. Analysis by Type of Liquid FDF
5.3.6.3. Analysis by Type of Powder FDF
5.3.6.5. Analysis by Type of FDF and Region
6. MANUFACTURING FACILITIES OF PHARMACEUTICAL CMOs IN CHINA
6.1. Chapter Overview
6.2. Pharmaceutical CMO Manufacturing Facilities in China
6.2.1. Facilities in Eastern China
6.2.1.1. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Location of Facility
6.2.1.2. Pharmaceutical CMO Manufacturing Facilities in Eastern China: Analysis by Company Size and Type of Product
6.2.2. Facilities in Northern China
6.2.2.1. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Location of Facility
6.2.2.2. Pharmaceutical CMO Manufacturing Facilities in Northern China: Analysis by Company Size and Type of Product
6.2.3. Facilities in Southern China
6.2.3.1. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Location of Facility
6.2.3.2. Pharmaceutical CMO Manufacturing Facilities in Southern China: Analysis by Company Size and Type of Product
7. PHARMACEUTICAL MANUFACTURING REGULATIONS IN CHINA
7.1. Chapter Overview
7.1.1. Health Authorities in China
7.1.2. Overview of Regulatory Guidelines in China
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. 2Y-Chem
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Aurisco Pharmaceutical
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. ChemPartner
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Dorrapharma
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. Hubei Biocause Pharmaceutical
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Infoark
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook
8.8. Ningbo Menovo Pharmaceutical
8.8.1. Company Overview
8.8.2. Service Portfolio
8.8.3. Recent Developments and Future Outlook
8.9. Shandong Xinhua Pharmaceutical
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. Recent Developments and Future Outlook
8.10. Shanghai Acebright Pharmaceuticals
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. Recent Developments and Future Outlook
8.11. STA Pharmaceutical
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. Zhejiang Huahai Pharmaceutical
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.4. Recent Developments and Future Outlook
9. BIG PHARMA INITIATIVES IN CHINA
9.1. Chapter Overview
9.2. Big Pharma Players: List of Initiatives
9.2.1. Analysis by Number of Initiatives
9.2.2. Analysis by Year of Initiative
9.2.3. Analysis by Company and Year of Initiative
9.2.4. Analysis by Type of Initiative
9.3. Benchmark Analysis of Big Pharmaceutical Players
9.3.1. Harvey Ball Analysis: Summary of Investments Made
9.3.2. Geographical Analysis by Investments Made (Facility Specific)
10. CASE STUDY: RECENT PARTNERSHIP TRENDS
10.1. Chapter Overview
10.2. Partnership Models
10.3. CMOs with Manufacturing Facilities in China: List of Recent Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Geography
10.4. CMOs with Manufacturing Facilities in China: Mapping Partnerships
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. CMOs with Manufacturing Facilities in China: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Chinese Manufacturing Facilities
11.3.2.1. Capacity Analysis: Eastern China
11.3.2.2. Capacity Analysis: Southcentral China
11.3.2.3. Capacity Analysis: Northern China
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2 Strengths
12.3. Weakness
12.4. Opportunities
12.5. Threats
12.6. Comparison of SWOT Factors
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030
13.4. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.4.1. Pharmaceutical Contract Manufacturing Services Market in Eastern China, 2020-2030
13.4.2. Pharmaceutical Contract Manufacturing Services Market in Southern China, 2020-2030
13.4.3. Pharmaceutical Contract Manufacturing Services Market in Northern China, 2020-2030
13.5. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Product
13.5.1. API Contract Manufacturing Services Market in China, 2020-2030
13.5.1.1. API Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.1.1.1. API Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.1.1.2. API Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.1.1.3. API Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030
13.5.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Geography
13.5.2.1.1. Drug Product Contract Manufacturing Services Market in Eastern China, 2020-2030
13.5.2.1.2. Drug Product Contract Manufacturing Services Market in Southern China, 2020-2030
13.5.2.1.3. Drug Product Contract Manufacturing Services Market in Northern China, 2020-2030
13.5.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Distribution by Type of Drug Product
13.5.2.2.1. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Solid Drug Product
13.5.2.2.2. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Liquid and Semi Solid Drug Product
13.5.2.2.3. Drug Product Contract Manufacturing Services Market in China, 2020-2030: Share of Injectable Drug Product
13.5.2.2.4. Drug product Contract Manufacturing Services Market in China, 2020-2030: Share of Other Drug Products
13.6. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Scale of Operation
13.6.1. Clinical Scale Contract Manufacturing Services Market in China, 2020-2030
13.6.2. Commercial Scale Contract Manufacturing Services Market in China, 2020-2030
13.7. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Distribution by Size of Manufacturers
13.7.1. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Small Companies
13.7.2. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Mid-sized Companies
13.7.3. Pharmaceutical Contract Manufacturing Services Market in China, 2020-2030: Share of Large / Very Large Companies
13.8. Concluding Remarks
14. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
15. CONCLUSION
15.1. Chapter Overview
15.2. Evaluation of Impact of COVID-19 Outbreak
15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. Wuxi AppTec
15.2.1.2. Porton Pharma Solutions
15.2.1.3. Lonza
15.2.2 Impact on China Pharmaceutical CMO Market Opportunity
15.3. Key Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate Steps
15.3.2. Short / Long Term Steps
16. APPENDIX 1: TABULATED DATA
Note: Product cover images may vary from those shown
  • 2Y-Chem
  • 3Waypharm
  • ABA Chemicals
  • AbbVie
  • Aescu Pharma
  • Agno Pharma
  • Allychem
  • Amgen
  • Anhui Biochem Biopharmaceutical
  • Anqiu Lu’an Pharmaceutical
  • Antengene
  • Apeloa
  • APIchem
  • APICMO
  • Ark Biosciences
  • Asymchem
  • Aurisco Pharmaceutical
  • Avery Chemical
  • Beijing Kawin Technology
  • Beijing Lunarsun Pharmaceutical
  • Beijing Mediking Biopharm
  • Beta Pharma
  • BioDuro
  • BioLingus
  • BLD Pharm
  • Bristol-Myers Squibb
  • Broad Pharmaceutical
  • C & O Pharmaceutical Technology
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Changzhou Carbochem
  • Changzhou Keylab Chemical
  • ChemFuture PharmaTech
  • ChemPartner
  • Chemsigma International
  • Chemspec Chemicals
  • Chemwill Asia
  • China Pharmaceutical Research and Development Center
  • Chinese Peptide
  • Chiral Quest
  • Chongqing Huabang Shengkai Pharmaceutical
  • Chongqing Pharmaceutical Research Institute
  • Cipla
  • Codexis
  • ComWin International
  • DC Chemicals
  • Dishman Group
  • Dizal Pharmaceutical
  • Dorrapharma
  • DSL Chemicals
  • Enantiotech
  • Enbridge PharmTech
  • EOC Pharma
  • Esteve Huayi Pharmaceutical
  • FarmaSino Pharmaceutical
  • Fine Industries
  • Flamma
  • Fountainbridge
  • Fresenius Kabi
  • GIHI CHEMICALS
  • Gilead Sciences
  • GlaxoSmithKline
  • Hangzhou DayangChem
  • Hangzhou Hysen Pharma
  • Hangzhou Panyu Chemical
  • Hangzhou Pharmco
  • Hangzhou Rongda Pharm & Chem
  • HangZhou Think Chemical
  • HD Biosciences
  • Hebei BRANT Pharmaceutical
  • Hebei Jiheng Pharmaceutical
  • Hetero
  • Hovione
  • Huayi Pharmaceuticals
  • Hubei Biocause Pharmaceutical
  • Hybio Pharmaceutical
  • Impact Therapeutics
  • Infoark
  • Jiangsu Allyrise Pharmaceutical
  • Jiangsu Baozong & Baoda Pharmachem
  • Jiangsu Hansyn Pharmaceutical
  • Jiangsu Quality Horizons Pharmtech
  • Jiangxi Fushine Pharmaceutical
  • JOINN Laboratories
  • Junye Pharmaceutical
  • Kingchem Life Sciences
  • Krka
  • Laviana Pharma
  • LEAPChem
  • Lianhetech
  • Lianhua Technology
  • Lonza
  • Luna Chemicals
  • Medichem
  • Merck
  • Nanjing Pharmatechs
  • NFTZ Alchem International
  • Ningbo Menovo Pharmaceutical
  • Novartis
  • Novasep
  • Pfizer
  • Pfizer CentreOne
  • PharmaBlock Sciences
  • PharmAgra Labs
  • Phoenix Molecular Designs
  • Pi chemicals
  • Piramal Pharma Solutions
  • Porton Pharma Solutions
  • Prisun Pharmachem
  • Qidong Accela ChemBio
  • Qingdao Kingway Pharmtech
  • Quantum
  • Raybow Pharm
  • Roche
  • SAGECHEM
  • Saniver
  • Sanofi
  • SciAnda (Changshu) Pharmaceuticals
  • Seacross Pharmaceuticals
  • Shandong Keyuan Pharmaceutical
  • Shandong Luxi Pharmaceutical
  • Shandong Xinhua Pharmaceutical
  • Shanghai Acebright Pharmaceuticals
  • Shanghai Ansion pharma Technology
  • Shanghai Fosun Pharmaceutical
  • Shanghai Hohance Chemical
  • Shanghai Pansopharm Technology
  • Shanghai Ruiyi Medical Tech
  • Shenzhen Jianyuan Pharmaceutical Technology
  • Siegfried
  • Sihuan Pharmaceutical
  • Sinolite
  • STA Pharmaceutical
  • Sundia MediTech
  • Sunwell
  • Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial
  • Suzhou Novartis Pharmaceutical Technology
  • Tai Heng Industry
  • TCI (Shanghai) Development
  • Tesaro
  • TIEN (Tianjin) Pharmaceutical
  • Topharman Shanghai
  • Venturepharma
  • Vesino
  • Vifor Pharma
  • Vitruvias Therapeutic
  • ViWA
  • Viwit Pharmaceuticals
  • Wisdom Pharmaceutical
  • WuXi AppTec
  • Xianju pharma
  • XINXIANG BEST PHARMACEUTICAL
  • YaoPharma
  • Yiling Pharmaceutical
  • Zhejiang Candorly Pharmaceutical
  • Zhejiang Changming Pharmaceutical
  • Zhejiang Dongjian Pharmaceutical
  • Zhejiang Excel Pharmaceutical
  • Zhejiang Haizhou Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Zhejiang Huahai Pharmaceutical
  • Zhejiang Jiuzhou Pharmaceutical
  • Zhejiang Langhua Pharmaceutical
  • Zhejiang Tianyu Pharmaceutical
  • Zhejiang Yongtai Technology
  • ZHIWE ChemTech
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...